ADAR1 Capital Management’s InMed Pharmaceuticals INM Stock Holding History

ADAR1 Capital Management’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.24M	Buy	+800,000	New	+$884K	0.06%	159

Other funds holding INM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Ursa Fund Management Danville, California $1.28B AUM 89.08% 1-Year Est. Return

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

ADAR1 Capital Management's INM Position: Q2 2026 in Review

ADAR1 Capital Management opened a new position in InMed Pharmaceuticals (INM) in Q2 2026: 800,000 shares worth $1.24M. The stake represents 0.06% of the portfolio and ranks #159 among its holdings.

20 funds tracked by Wall St. Rank hold INM as of Q2 2026.

ADAR1 Capital Management held 800,000 shares of InMed Pharmaceuticals worth $1.24M as of Q2 2026.
InMed Pharmaceuticals was a new ADAR1 Capital Management position in Q2 2026.
InMed Pharmaceuticals made up 0.06% of ADAR1 Capital Management's portfolio in Q2 2026, its #159 holding.
20 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.